Research Papers:

Soluble Toll-like receptor 4 is a potential serum biomarker in non-small cell lung cancer

Feng Wei _, Fan Yang, Jing Li, Yu Zheng, Wenwen Yu, Lili Yang and Xiubao Ren

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:40106-40114. https://doi.org/10.18632/oncotarget.9496

Metrics: PDF 1698 views  |   HTML 2334 views  |   ?  


Feng Wei1,3,4, Fan Yang2,3,4, Jing Li1,3,4, Yu Zheng2,3,4, Wenwen Yu1,3,4, Lili Yang1,3,4, Xiubao Ren1,2,3,4

1Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, PR China

2Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, PR China

3National Clinical Research Center for Cancer, Tianjin, PR China

4Tianjin Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, PR China

Correspondence to:

Xiubao Ren, email: [email protected]

Keywords: soluble Toll-like receptor 4 (sTLR4), non-small cell lung cancer (NSCLC), high-mobility group box 1 (HMGB1), biomarker

Received: January 11, 2016    Accepted: May 05, 2016    Published: May 20, 2016


This study investigated the clinical significance of serum soluble Toll-like receptor 4 (sTLR4) in non-small cell lung cancer (NSCLC). A total of 54 NSCLC patients and 13 healthy volunteers were enrolled from January 2012 to December 2013. The patients with NSCLC were characterized by significantly higher serum levels of sTLR4 compared with those in healthy controls (P < 0.01). A positive correlation between serum sTLR4 and tumor stage was found in patients with stages I–III NSCLC. However, serum sTLR4 in patients with metastatic NSCLC was significantly decreased compared with those with stage III NSCLC (P < 0.05). Furthermore, low serum sTLR4 was identified as a prognostic marker for poor survival of early-stage NSCLC patients who received surgical resection. In conclusion, our present study identified sTLR4 as a potential serum biomarker of NSCLC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9496